NCT06779721

Completed

Sestrin-2 Levels and Insulin Resistance

Kayseri City Hospital Source

Other study identifiers

Sponsor study identifier

425/2021

Study Type

observational

Actual enrollment (reported)

89

Locations

1 country

Sites

1

Timeline

Study Start

June 20, 2021

Actual (reported)

Primary Completion

January 20, 2022

Actual (reported)

Study Completion

February 15, 2022

Actual (reported)

Brief Summary

The aim of this study is to evaluate sestrin-2 levels in children with obesity

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 89 participants
Study completion date: February 15, 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 20, 2021
Actual (reported)
Primary Completion
January 20, 2022
Actual (reported)
Study Completion
February 15, 2022
Actual (reported)
First Submitted
January 13, 2025
Actual (reported)
First Posted
January 16, 2025
Actual (reported)

Last Updated: January 17, 2025
Status Verified: January 2025
Last Update Submitted: January 16, 2025

Conditions

Obese Adolescents

Keywords

Antioxidantchildhood obesityinsulin resistancesestrin-2oxidative stress

Outcome Measures

Primary Outcomes (1)

Evaluation of sestrin-2 levels in obese and healthy participants
From enrollment to the end of 6 months

Interventions

Sestrin-2Other

Sestrin-2 levels were studied in three different groups

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age10 Years - 18 Years

Sexall

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

Obese and healthy adolescents who admitted to Kayseri City Hospital

You may qualify if:

Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2

You may not qualify if:

Sponsors & Collaborators

Kayseri City Hospital
Governmentlead

Study Sites (1)

Kayseri City Hospital

Kayseri, 38125, Turkey (Türkiye)

Related Publications (1)

Soylu Ustkoyuncu P, Kocer D. Sestrin-2 levels and insulin resistance in childhood obesity. J Investig Med. 2026 Apr;74(3):254-259. doi: 10.1177/10815589251359311. Epub 2025 Jul 7.
PMID: 40621934DERIVED

MeSH Terms

Conditions

Pediatric ObesityInsulin Resistance

Interventions

Sesn2 protein, rat

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Enrollment

89 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

January 13, 2025

First Posted

January 16, 2025

Study Start

June 20, 2021

Actual (reported)

NCT07120516

Co-creating School Community Intervention Program on Physical Activity to Increase Health Equity in Children and Adolescents

Recruiting

NCT04794244

Healthy Living in Overweight and Obese Adolescents ASGE-FABES Program in Development of Formats

Not ApplicableCompleted

NCT06755827

Pilot Testing a Novel Approach to Pediatric Obesity Treatment

Phase 1/2Recruiting

NCT07103889

Effect of Acute Exercise on Biochemical Parameters in Normal-Weight and Overweight/Obese Adolescent.

Not ApplicableCompleted

NCT06626295

Exercise-snacks for Breaking the Sedentary Lifestyle and Improving the Physical Fitness of Obese Adolescents?

Not ApplicableRecruiting

NCT06914765

ESG in Obese Adolescents

Not ApplicableEnrolling By Invitation

Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes

Contact the study team to confirm eligibility.

Primary Completion

January 20, 2022

Actual (reported)

Study Completion

February 15, 2022

Actual (reported)

Last Updated

January 17, 2025

Record last verified: 2025-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06779721
Data provider: ClinicalTrials.gov
Source updated: 2025-01-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:36:01 UTC

Locations

TR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Source record

Locations